Anti-CAIX Antibody-drug Conjugate BAY79-4620

**Semantic type:** Amino Acid, Peptide, or Protein|Pharmacologic Substance

**Definition:** An antibody-drug conjugate (ADC) composed of 3ee9, a monoclonal antibody directed against the tumor-associated antigen (TAA) carbonic anhydrase IX (CAIX; carbonic anhydrase 9; CA9; G250), conjugated via a valine-citrulline (VC) peptide linker to the auristatin derivative and microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration of anti-CAIX ADC BAY79-4620, the monoclonal antibody moiety 3ee9 targets and binds to CAIX expressed on tumor cells. Upon internalization, proteolytic cleavage of linker, and the release of MMAE, MMAE targets and binds to tubulin, and inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest and apoptosis in CAIX-expressing tumor cells. CAIX is a member of the carbonic anhydrase family that is found in a majority of renal cell carcinomas while absent in most normal tissues.

**Synonyms:** - ADC BAY79-4620 - Anti-CAIX ADC BAY79-4620 - Anti-CAIX/MMAE ADC BAY79-4620 - BAY 794620 - BAY79-4620